Impact of Clinical Pharmacist Support on Oral Cancer Treatments Evaluating Patient Compliance and Follow-up Care in Oncology

What this Trial Is About

Researchers are evaluating the role of hospital pharmacists at the start of oral cancer treatments taken at home. This study aims to see how pharmaceutical monitoring at treatment initiation affects patient adherence, management of side effects, and overall treatment follow-up. The focus is on patients with solid tumors who begin oral therapy for cancer, excluding blood cancers. Participants are randomly assigned to one of two groups one receiving a specialized pharmaceutical consultation at the hospital plus follow-up communication between hospital and community pharmacists, and the other receiving only the initial pharmaceutical consultation. The follow-up includes contacting the patients local pharmacy to ensure treatment continuity and monitoring for issues such as missed refills or side effects. This approach compares standard pharmaceutical consultation with enhanced monitoring and coordination. During the study, patients will be assessed for treatment adherence at 3 and 6 months using the Girerd questionnaire. Researchers will track side effect management and treatment continuation through records kept by the pharmacists. The study emphasizes collaboration between hospital and community pharmacies to support patients throughout their oral cancer therapy. Participation involves regular monitoring and follow-up over several months to evaluate compliance and optimize care.

Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.